Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets

v3.5.0.2
Intangible Assets
 6 Months Ended
Jun. 30, 2016
Intangible Assets  
Intangible Assets

5.    Intangible Assets

 

The Company’s intangible assets consist of the following:

 

 

 

 

 

 

 

 

 

 

    

June 30,

    

December 31,

    

 

 

2016

 

2015

 

 

 

 

 

 

 

 

License agreements

 

$
907,545

 

$
897,594

 

Patents

 

 
267,387

 

 
179,997

 

Less: accumulated amortization

 

 
(431,542)

 

 
(399,509)

 

Intangible assets, net

 

$
743,390

 

$
678,082

 

 

License agreements are being amortized over periods ranging from 17-20 years. Patent costs were being amortized over three years. As of June 30, 2016, the patents were fully amortized, and the remaining patents of $267,387 were pending patent costs and were not amortizable. Amortization expense was approximately $16,000 and $11,000 for the three months ended June 30, 2016 and 2015, respectively, and approximately $32,000 and $23,000 for the six months ended June 30, 2016 and 2015, respectively. As of June 30, 2016, future amortization of license agreements for the remainder of this year and the next seven years is expected to be $32,000 for 2016, $64,000 for 2017 through 2022 and $60,000 for 2023.

 

License Agreements

 

The Company has entered into multiple license agreements (the “License Agreements”) with the University of Florida Research Foundation and the University of Texas at Austin. Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:

 

·

AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%; 

 

·

If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor. Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own use of the technologies;

 

·

AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and

 

·

Currently, under the University of Texas at Austin’s agreement, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee.  A Milestone fee to the University of Florida Research Foundation of $2,000 is due if AxoGen receives FDA approval of its Avance® Nerve Graft, $25,000 upon first commercial use of certain licensed technology to provide services to manufacture products for third parties and $10,000 upon first use to manufacture products that utilize certain technology that is not currently incorporated into AxoGen products.

 

Royalty fees were approximately $217,000 and $121,000 during the three months ended June 30, 2016 and 2015, respectively, and approximately $370,000 and $217,000 for the six months ended June 30, 2016 and 2015, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations.